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Background/aim: COVID-19 pandemic created concerns among patients receiving immunosuppressive therapy. Frequency of COVID-19
and impact of lockdown on treatment compliance in patients with vasculitis are largely unknown.
Materials and method: Patients with ANCA-associated and large vessel vasculitis that have been followed-up in our clinic were contacted by
phone and a questionnaire containing home isolation status, treatment adherence and history of COVID-19 between March 1st and June 30th,
2020 was applied.
Results: The survey was applied to 103 patients (F/M: 59/44, mean age: 53.2±12.5). Thirty-three (32%) patients didn’t attend at least one
appointment; 98(95.1%) noted that they spent 3 months in home isolation. Five patients (4.8%) received immunosuppressives irregularly and
3(2.9%) developed symptoms due to undertreatment. Four (3.9%) patients admitted to hospital with a suspicion of COVID-19, but none of
them had positive PCR or suggestive findings by imaging. COVID-19 was diagnosed in a patient with granulomatosis with polyangiitis during
hospitalization for disease flare and she died despite treatment.
Conclusion: Frequency of COVID-19 was low in patients with vasculitis in our single center cohort. Although outpatient appointments were
postponed in one-third of our patients, high compliance with treatment and isolation rules ensured patients with vasculitis overcome this
period with minimal morbidity and mortality.
Key words: COVID-19, ANCA-associated vasculitis, large vessel vasculitis, treatment adherence, compliance

1. Introduction
The COVID-19 pandemic has created an alarming situation
in patients with autoimmune disease receiving
immunosuppressive treatment, in terms of predisposition to
infection. There is limited data on the effect of rheumatic
disease and immunosuppressive therapy on the prognosis of
COVID-19 disease. Monti et al. suggested that the presence of
rheumatic disease will not negatively affect the course of
COVID-19; whereas Gianfresco et al. reported that the use of
corticosteroids (CS) above 10 mg/day increases
hospitalization. It was reported that the use of anti-TNF
agents reduces the risk of hospitalization [1,2]. Among the
autoimmune diseases, systemic vasculitis constitutes a variety
of conditions including granulomatosis with polyangiitis
(GPA), microscopic polyangiitis (MPA), eosinophilic
granulomatosis with polyangiitis (EGPA), Takayasu arteritis
(TA), and giant cell arteritis (GCA). These rare diseases can
cause morbidity and mortality, however the additional effect
of COVID-19 on prognosis of systemic vasculitis is yet
unknown.

In Turkey, over two hundred thousand COVID-19 cases
were reported between March-June 2020. Most of the cases
were residing in Istanbul. In order to prevent the spread of
COVID-19, the following measures were taken: periodic
curfews and quarantine were implemented; employees
receiving immunosuppressive therapy were given
administrative leave and patients allowed to receive their
routine treatment without prescription. Some health
institutions have been transformed into "pandemic hospitals"
and most inpatient units had served COVID-19 patients,
during this period. Physicians of all branches, including
internal medicine and rheumatology specialists, were
assigned to these COVID-19 units periodically. Therefore,
outpatient appointments significantly decreased and periodic
follow-up visits were postponed. This situation caused
disruption or delay in the treatment of patients, especially for
those with vital organ involvement.
In a survey study including 770 patients followed-up in
rheumatology clinics, 22% of them were reported to be
noncompliant with treatment due to concerns about infection
[3]. Considering the complications due to possible disease
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flares, treatment compliance is an important issue [4]. In our
study, we aimed to evaluate the effect of COVID-19 and the
quarantine period on disease activity and treatment
compliance in patients with various systemic vasculitis, by
applying a telephone survey to our patients who have been
regularly followed up in our vasculitis clinic.
2. Patients and methods
Patients with GPA, MPA, TA, and GCA who have been
followed by the Department of Rheumatology at Istanbul
Faculty of Medicine, and whose last outpatient visit were after
July 1st, 2019, were included in this study. Ethics committee
approval was received from the Istanbul University Istanbul
Faculty of Medicine Ethics Committee (Date-Number: 2020937).
Each patient was reached out by phone calls from
20/07/2020 to 31/07/2020. Patients who had at least
one outpatient visit in between 1 March–30 June 2020 were
excluded and assessed separately. After reading the voluntary
consent form verbally and obtaining consent from the
patients, an 11-question-survey was applied to the
participants (Table 1). Patients with hospital admission
and/or hospitalization history were invited to the clinic and
their records were evaluated. The survey data were evaluated
by being digitized using the IBM SPSS Statistics for Windows
(v. 21.0. Armonk, NY: IBM Corp.) program. The continuous
variables are presented as the mean (SD) or median (IQR),
whereas the categorical variables are presented as a number
and percentage. Normality tests were performed with
Kolmogorov–Smirnov or Shapiro tests. For categorical
comparisons, the Chi-square and Fisher’s tests were used.
Student’s t-test and Mann–Whitney U test were used for the
comparison of continuous variables, according to the
normality of the data. A p value less than 0.05 was accepted as
statistically significant.
3. Results
In a cohort of 211 patients with vasculitis whose last visit were
within one year, forty-nine patients with systemic vasculitis
(30 AAV, 15 TA, 4 GCA) attended their outpatient
appointment between March 1 and June 30. None of these
patients reported symptoms that might be associated with
COVID-19 (fever, upper or lower respiratory system
symptoms, nausea or diarrhoea). After exclusion of these
patients, a total of 103 available patients (F/M: 59/44, median
age: 57 ± 15.4 (25–84)) were included into the survey by
phone call (Figure). Patients were being followed up with the
diagnosis of GPA; 54 (52.4%), MPA; 15 (14.5%), TA; 22
(21.4%), GCA; 12 (11.6%).
The mean follow-up period was 84.6 ± 51.4 months (9–
251). Fifty-four (52.4%) patients were receiving only oral
drugs, 41 (39.8%) parenteral treatment and 8 (7.8%) patients
were followed up without treatment. Patient characteristics
were described in Table 2. Eighty-five patients (82.5%) were
on corticosteroids. Thirty-five (33.9%) patients were receiving
intravenous treatments requiring periodic hospital
admissions (26 rituximab (RTX), 6 infliximab (IFX), 1
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Table 1. Questions of survey applied to the participants.
Questions
1- When was your last outpatient appointment?
2- Which medications do you take regularly?
3- Did you take your medications regularly during past 3 months?
4- Was there any interruption or delay in your treatments you
received regularly in hospital settings?
5- Have you had any complaints that you think are related to your
illness?
6- Did you continue to work during the pandemic?
7- Did you self-isolated at home during pandemic?
8- Have you applied to a health institution with complaints such as
fever, cough, shortness of breath, smell and taste, abdominal pain
and diarrhea in the 3-month period?
If yes:
- Was a nose or mouth sample collected for COVID-19 there?
- If so, do you know the result?
- Did you need to be hospitalized with the diagnosis of COVID19?
9- Did your households members continued to work?
10- Have any of your household members applied to a health
institution with complaints such as fever, cough, shortness of
breath, smell and taste, abdominal pain and diarrhea in the 3month period?
If yes:
- Was a nose or mouth sample collected for COVID-19 collected?
- If so, do you know the result?
11- If you continue to work, has anyone in your work environment
been diagnosed with COVID-19?
COVID-19: Coronavirus disease-19.

cyclophosphamide (CYC) (monthly pulse), and 2 intravenous
immunoglobulin (IVIG)).
The average time from the last appointment to the survey
date was 5.2 ± 2.6 (1–12) months. Thirty-three (32%) patients
missed at least one outpatient appointment. Patients with a
diagnosis of AAV and LVV were 24 and 9, respectively. Six of
these patients (18.2%) were on parenteral treatment (3 RTX,
2 Tocilizumab, 1 CYC (monthly pulse)). There was no
statistically significant difference between these groups in
terms of age, sex, and disease subtypes (Table 3). Attendance
rate for appointments was higher among patients who use
parenteral treatment in comparison to oral treatment (35/41
vs. 31/54 p = 0.003 OR: 2.9 %95 CI 1.3–6.5).
Ninety-eight patients (95.1%) spent 3 months in home
isolation while 2 (1.9%) patients continued to work. Thirtyeight (36.9%) patients’ relatives who live in the same house
continued working. Among the relatives of these patients,
three (2.9%) were treated as outpatients with the diagnosis of
COVID-19 but all were RT-PCR negative. Five (4.8%)
patients (1 GPA, 2 TA, 2 GCA) stated that they received their
treatments irregularly during this period. One TA patient was
receiving azathioprine; four patients were receiving parenteral
therapy (Table 4). All patients stated that they did not use
their treatment regularly due to concerns about
immunosuppressive therapy during pandemic. Symptoms
were thought to be developed due to under treatment in three
of the patients (2.9%), and treatment was restarted in these
patients after COVID-19 had been ruled out.
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Figure. Flowchart of participation into the study. GCA: giant cell arteritis, GPA: granulomatosis with polyangiitis, MPA: microscopic
polyangiitis, TA: Takayasu arteritis.

Four patients (3.9%) (2 GPA, 1 TA and 1 GCA) stated that
they applied to the hospital with a suspicion of COVID-19 in
the 3-month period. COVID-19 RT-PCR tests and thorax CT
imaging were negative in all four patients and they received
symptomatic treatment only. Our survey revealed that two
patients who were called had died earlier. Patient #1 was a 60year-old patient with a 5-year history of GPA and 1-year
history of metastatic bladder carcinoma. His last outpatient
appointment was in December 2019. The assessment of
records showed that he was in remission under low-dose CS
treatment and died due to pericardial metastasis of carcinoma
and cardiac tamponade before the pandemic period (January
2020).
Patient #2 was a 37-year-old female patient with GPA
diagnosed in 2006. She developed end-stage renal failure
during disease course. She was in clinical remission in her last
outpatient visit in December 2019, despite her high titer antiPR3 positivity. She missed her follow-up visit in April 2020
due to the quarantine process, later on she was admitted in
Intensive Care Unit (ICU) in May 2020 due to diffuse alveolar

haemorrhage. Before the admission, the patient stated that she
was compliant with her treatment and she had no known
COVID-19 contacts. During induction therapy with high
dose corticosteroids and plasmapheresis, her control COVID19 RT-PCR resulted positive. Tocilizumab (400 mg IV) was
administered due to development of macrophage activation
syndrome on the 7th day but after 16 days of ICU follow-up,
she died due to sepsis and multiorgan failure.
4. Discussion
In this study, we aimed to determine the effects of the
pandemic on the clinical course in patients with systemic
vasculitis and the frequency of COVID-19 in our patient
population. Nearly half of our patients, most of whom are
diagnosed with small vessel vasculitis, have been receiving
parenteral treatment and one-third have been receiving
intravenous treatments that required periodic hospitalization.
Five patients were noncompliant with their treatment and 4
(80%) of these patients were followed up with the diagnosis of
large vessel vasculitis. Considering that the majority (67%) of
2245
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Table 2. Patient characteristics.
ANCA associated vasculitis

Large vessel vasculitis

GPA (n = 54)

MPA (n = 15)

TA (n = 22)

GCA(n = 12)

Age (median ± SD; (IQR))

51 ± 16 (24)

57 ± 15.2 (15)

39 ± 13.5 (21.5)

71 ± 9.4 (8.5)

Sex (F/M)

26/28

6/9

20/2

8/4

PR3-ANCA (+)

33

0

-

-

MPO-ANCA (+)

10

14

-

-

LRS involvement

45

11

-

-

Renal involvement

36

10

-

-

Peripheral nerve involvement

5

4

-

-

Chronic renal disease

18

6

2

0

Patients skipped at least one outpatient visit

20

4

5

4

Patients with treatment inadherence

1

0

2

2

AAV: ANCA associated vasculitis, GCA: giant cell arteritis, GPA: granulomatosis with polyangiitis, LRS: lower respiratory system, LVV:
large vessel vasculitis, MPA: microscopic polyangiitis, MPO: myeloperoxidase, PR3: proteinase-3 TA: Takayasu arteritis.
Table 3. Comparison of patients who skipped and did not skip their appointments.
Patients who skipped at least one
Patients who did not skip
p
appointment (n = 33)
appointment (n = 70)
Male sex (%)
15 (62.5%)
24 (34.3%)
0.27*
Age (median ± SD;
59 ± 16.1; 24
51.5 ± 15.1; 22.3
0.3Ŧ
IQR)
AAV/LVV
24/9
44/26
0.32*
AAV: ANCA associated vasculitis, IQR: interquatile range, LVV: iarge vessel vasculitis, SD: standard deviation, *chi-square test ŦMann–
Whitney U test.
Table 4. Description of patients who had treatment inadherence during 3-month period.
Age

Diagnosis

Treatment
CS + CYC
(monthly)

Skipped doses

Complaint

Final assessment

Case #1

63

GPA

2

none

Treatment restarted

Case #2

48

TA

Tocilizumab
4
(weekly)

back pain,
arm
cladicaution

Patients’ complaints diminished after re-admission of
treatment

Case #3

38

TA

CS + AZA

Case #4

73

GCA

Tocilizumab
unknown
(weekly)

Used half dose
back pain
at her own will
none

After negative COVID-19 RT PCR result, complaints are
thought to be due to disease activity and treatment
restarted
Treatment restarted

After negative COVID-19 RT PCR result, complaints are
thought to be due to disease activity and treatment
restarted
AZA: azathioprine, CS: corticosteroids, CYC: cyclophospamide, GCA: giant cell arteritis, GPA: granulomatosis with polyangiitis, TA:
Takayasu arteritis.
Case #5

67

GCA

Tocilizumab
12
(weekly)

weakness,
fever

the patients surveyed had ANCA-associated vasculitis (AAV),
although nearly forty percent (24/64) of these patients skipped
at least one visit, it was concluded that the treatment
compliance of these patients were acceptable. Low rate of
treatment inadherence during this period may be related to
awareness of the patients about the clinical course of their
disease and their use of oral treatment options. Hospital
admission requirement for intravenous treatments was
thought to be the main reason for the higher rate of
attendance to clinic appointments in patients using parenteral
drugs.
Our inpatient and outpatient clinics remained open
during the 3-month period and all patients received their
2246

infusion treatments except for one GPA patient (2.9%) who
received monthly intravenous cyclophosphamide treatment.
In a survey study conducted in the Lombardy region of Italy,
revealed that higher proportion of patients (15%) TA patients
who received infliximab treatment could not continue their
infusion treatments [5]. Especially in this patient group with
severe organ and/or life-threatening disease involvement,
higher sustainability of treatment was considered to be one of
the most important factors in low mortality. Furthermore,
rarity of evident disease exacerbation during the study period
supports this view.
During the 3-month period, four (3.9%) patients were
admitted to emergency outpatient clinics with various
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complaints, all of them were found to have negative COVID
RT- PCR tests without clear evidence of COVID-19 by thorax
imaging. COVID-19 was excluded in these patients due to
their asymptomatic course and negative RT-PCR tests. Our
patients have low COVID-19 prevalence, which may be
related to the patient's awareness of their high-risk status
about COVID-19 due to receiving immunosuppressive
treatment and as a result compliance with preventive
measures. Also, their family members or close contacts may
contribute to this outcome with prioritizing preventive
measures. Since the results of the COVID-19 seroprevalence
study conducted in our country have not been published yet,
it was not possible to compare the prevalence of infection in
the study group with the normal population.
The patient with GPA who was hospitalized in the
intensive care unit (ICU) with alveolar hemorrhage, was
administered tocilizumab due to the findings of COVID-19
associated macrophage activation syndrome. During followup, she died due to possible secondary bacterial infection.
Based on the data regarding endothelial dysfunction and
microvascular thrombosis in COVID-19 patients [6]; it can be
speculated that; infection may have triggered disease relapse
in our patient. Thus, it is plausible that coexistence of these
two conditions had worsened the prognosis.
Our study is one of the first studies with a considerable
number of patients with systemic vasculitis in Turkey during
the COVID 19-pandemic. Patients are followed-up in a single
center and the survey is conducted by the clinicians who
follow the patients; these may be important in terms of
representing the clinical data more accurately and detecting
treatment interruptions more reliably.
In order to prevent hospital acquired infections during the
pandemic, the telephone-survey is a useful method with
known limitations such as high number of unavailable or
refusing patients and lack of detailed answers. Due to the high
risk of infection, patients without complaints were not invited
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